Abstract: Described herein is a multiplexed and high content screening assay using primary neurons for identifying small molecule modulators of neuronal mitochondrial mitostasis (MnMs). Also described is a high throughput screening assay using primary neurons for identifying small molecules that increase mitochondrial function, identified by measuring the electrochemical potential across the inner mitochondrial membrane and ATP generation. Most MnMs that increased mitochondrial content, length and/or health also increased mitochondrial function without altering neurite outgrowth. Some MnMs protect mitochondria in primary neurons from A?(1-42) toxicity, glutamate toxicity, increased oxidative stress and the toxic cellular environment associated with Alzheimer's disease. Some MnMs target mitochondria directly. An MnM also increases the synaptic activity of hippocampal neurons and is potent in vivo, increasing the respiration rate of brain mitochondria after administering the compound to mice.

Abstract: The present invention relates to highly soluble, non-fluorescent and photostable myosin inhibitors; especially, for in vivo inhibition of the ATPase activity of neuronal non-muscle myosin 2 of formula (II): wherein Q1, Q2, Q3, Q4, R1, R2, R4 and R5 are as defined in claim 1. The invention also relates to pharmaceutical compositions or medicaments comprising the compounds of the invention and processes for manufacturing these compounds and their intermediates.

Abstract: The present invention relates to highly soluble, non-fluorescent and photostable myosin inhibitors; especially, for in vivo inhibition of the ATPase activity of neuronal non-muscle myosin 2 of formula (II): wherein Q1, Q2, Q3, Q4, R1, R2, R4 and R5 are as defined in claim 1. The invention also relates to pharmaceutical compositions or medicaments comprising the compounds of the invention and processes for manufacturing these compounds and their intermediates.